Charles River Laboratories International (CNSX:CRL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
Earnings and Valuation
This table compares Charles River Laboratories International and BARD1 Life Sciences' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Charles River Laboratories International | N/A | N/A | N/A | N/A | N/A |
BARD1 Life Sciences | $612,251.00 | 0.00 | $-6,644,706.43 | A($0.08) | N/A |
Charles River Laboratories International has higher earnings, but lower revenue than BARD1 Life Sciences.
Profitability
This table compares Charles River Laboratories International and BARD1 Life Sciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Charles River Laboratories International | N/A | N/A | N/A |
BARD1 Life Sciences | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of recent ratings for Charles River Laboratories International and BARD1 Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Charles River Laboratories International | 0 | 0 | 0 | 0 | N/A |
BARD1 Life Sciences | 0 | 0 | 0 | 0 | N/A |
Summary
BARD1 Life Sciences beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.